BioXcel Therapeutics (BTAI) Total Current Liabilities (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Total Current Liabilities of $55.0 million for Q1 2026, up 115.27% year-over-year from $25.5 million in Q1 2025, and up 1.98% quarter-over-quarter from $53.9 million in Q4 2025.
BioXcel Therapeutics (BTAI) Total Current Liabilities (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $55.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 115.27% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (up 115.27% YoY), while the FY2025 annual figure was $53.9 million, up 142.55% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $55.0 million, up from $53.9 million in the prior quarter.
- The five-year high for Total Current Liabilities was $55.0 million in Q1 2026, with the low at $16.0 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $28.8 million (2023), against an average of $31.5 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 35.15% in 2024, then soared 142.55% in 2025.
- BioXcel Therapeutics' Total Current Liabilities stood at $32.9 million in 2022, then dropped by 17.12% to $27.3 million in 2023, then decreased by 18.46% to $22.2 million in 2024, then jumped by 142.55% to $53.9 million in 2025, then rose by 1.98% to $55.0 million in 2026.
- Business Quant data shows BTAI's Total Current Liabilities at $55.0 million in Q1 2026, $53.9 million in Q4 2025, and $37.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.34 Bn | 43.37 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.96 Bn | 40.30 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 32.44 Bn | 30.77 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.97 Bn | 18.09 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.54 Bn | 15.16 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.96 Bn | 11.43 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.15 Bn | 9.99 Bn | - | 1.79 Bn |
| 10 | BioXcel Therapeutics | 25.16 Mn | 25.16 Mn | 160,000.00 | 137.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.15 Mn |
| Mar 31, 2026 | 54.99 Mn |
| Dec 31, 2025 | 53.93 Mn |
| Sep 30, 2025 | 37.80 Mn |
| Jun 30, 2025 | 33.38 Mn |
| Mar 31, 2025 | 25.55 Mn |
| Dec 31, 2024 | 22.23 Mn |
| Sep 30, 2024 | 25.56 Mn |
| Jun 30, 2024 | 27.29 Mn |
| Mar 31, 2024 | 31.48 Mn |
| Dec 31, 2023 | 27.27 Mn |
| Sep 30, 2023 | 39.41 Mn |
| Jun 30, 2023 | 34.74 Mn |
| Mar 31, 2023 | 28.76 Mn |
| Dec 31, 2022 | 32.90 Mn |
| Sep 30, 2022 | 23.38 Mn |
| Jun 30, 2022 | 20.00 Mn |
| Mar 31, 2022 | 16.00 Mn |
| Dec 31, 2021 | 16.67 Mn |
| Sep 30, 2021 | 14.60 Mn |